Benzinga | Sep 10, 2021 07:45AM EDT

Wedbush Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $39

Wedbush analyst Laura Chico downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Outperform to Neutral and lowers the price target from $71 to $39.